gprc5d-car-t
Cell therapyexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2021 (NCT05016778)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- G-protein coupled receptor family C group 5 member DImmunity, passive
immunity, passive - gprc5d
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05749133 | Phase 1/Phase 2 (Phase 2) | Apr 10, 2023 | China Academy of Chinese Medical Sciences |
| NCT05759793 | Phase 1 | Mar 30, 2023 | IASO Pharma Inc., Jiao Tong University |
| NCT05739188 | Phase 1/Phase 2 (Phase 2) | Feb 7, 2023 | People's Liberation Army of China |
| NCT05325801 | Phase 1 | Apr 30, 2022 | Zhejiang University |
| NCT05219721 | Phase 1 | Mar 17, 2022 | Huazhong University of Science and Technology, IASO Pharma Inc. |
| NCT05016778 | Early Phase 1 (Phase 1) | Jun 8, 2021 | Shanghai OriginCell Therapeutics Co., Ltd., Zhejiang University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IASO Pharma Inc. | For profit | 2 | 1 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2023 |
| Shanghai OriginCell Therapeutics Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1